• 1. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 4. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 5. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100

Research Brief on 2-(3-Ethylphenyl)pyrrolidine (CAS: 1270480-16-4) in Chemical Biology and Pharmaceutical Applications

2-(3-Ethylphenyl)pyrrolidine (CAS: 1270480-16-4) is a chemical compound of growing interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its pyrrolidine core and 3-ethylphenyl substituent, has recently emerged as a potential scaffold for drug discovery due to its unique physicochemical properties and biological activity. Recent studies have explored its applications in central nervous system (CNS) disorders, pain management, and as a building block for more complex pharmacologically active molecules.

A 2023 study published in the Journal of Medicinal Chemistry investigated the dopamine receptor binding affinity of 2-(3-Ethylphenyl)pyrrolidine derivatives. The research team synthesized a series of analogs and found that specific substitutions on the pyrrolidine ring could significantly enhance selectivity for D2-like receptors. Molecular docking simulations suggested that the ethyl group at the 3-position of the phenyl ring contributes to optimal hydrophobic interactions with receptor subpockets, making this compound a promising lead for developing novel antipsychotic medications.

In neuropharmacology research, 2-(3-Ethylphenyl)pyrrolidine has shown modulatory effects on sigma receptors, particularly σ1, which are implicated in neuroprotection and pain perception. A recent preclinical study demonstrated that this compound could attenuate neuropathic pain in animal models through σ1 receptor antagonism, with reduced off-target effects compared to currently available analgesics. These findings were presented at the 2024 International Symposium on Pain Research and have sparked interest in developing non-opioid pain therapeutics based on this chemical scaffold.

The compound's metabolic stability and blood-brain barrier permeability have been systematically evaluated in recent ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) studies. Data from these investigations indicate that 2-(3-Ethylphenyl)pyrrolidine exhibits favorable pharmacokinetic properties, with moderate plasma protein binding and acceptable hepatic clearance rates. These characteristics make it particularly attractive for CNS-targeted drug development programs.

Emerging applications in chemical biology include the use of 2-(3-Ethylphenyl)pyrrolidine as a molecular probe to study protein-ligand interactions. Researchers have successfully incorporated radioisotope labels (e.g., 11C) at the ethyl group position, enabling positron emission tomography (PET) imaging studies of receptor distribution in vivo. This technique has provided valuable insights into receptor occupancy dynamics for several CNS-targeted therapeutics currently in clinical development.

From a synthetic chemistry perspective, recent advances have improved the scalability and enantioselective synthesis of 2-(3-Ethylphenyl)pyrrolidine. A 2024 publication in Organic Process Research & Development described a novel asymmetric hydrogenation protocol that achieves >99% ee with excellent yield, addressing previous challenges in obtaining optically pure forms of this compound. This methodological breakthrough is expected to facilitate more extensive structure-activity relationship studies.

While the therapeutic potential of 2-(3-Ethylphenyl)pyrrolidine is promising, current research also highlights the need for further optimization. Structure-activity relationship studies suggest that modifications to the pyrrolidine nitrogen or introduction of heteroatoms in the phenyl ring could enhance target selectivity and reduce potential side effects. Several pharmaceutical companies have included derivatives of this compound in their preclinical pipelines, with anticipated IND submissions within the next 2-3 years.

• 59347-91-0((2S)-2-phenylpyrrolidine)
• 3466-80-6(2-Phenylpiperidine)
• 106366-30-7(2-(2-phenylethyl)pyrrolidine)
• 58613-54-0((2R)-2-phenylpiperidine)
• 383129-36-0(2-(3-methylphenyl)azepane)
• 1006-64-0(2-Phenylpyrrolidine)
• 121193-91-7(2-(Naphthalen-1-yl)pyrrolidine)
• 56523-47-8((2R)-2-phenylpyrrolidine)
• 3466-82-8(2-Phenylazepane)
• 383131-04-2(2-(naphthalen-2-yl)azepane)